争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 10 条
2024
2023
AbbVie就Brukinsa对BeiGene提起专利诉讼
提起诉讼
AbbVie旗下Pharmacyclics部门在特拉华州联邦法院起诉BeiGene,指称BeiGene的Brukinsa侵犯了AbbVie的Imbruvica专利。AbbVie寻求侵权宣告及赔偿;BeiGene表示将积极应对这些指控。
当事方说明的目的. AbbVie寻求侵权宣告及赔偿。
品牌回应
否认 — BeiGene
BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.
来源摘录
Through its complaint, filed the same day in federal court in Delaware, US, AbbVie is seeking a declaratory judgment of infringement, as well as damages.
AbbVie’s Pharmacyclics unit has filed a lawsuit against BeiGene, alleging that the biotech’s Brukinsa (zanubrutinib) infringes a patent on its own blood cancer drug Imbruvica (ibrutinib).
BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.
2022
2021
2021
BTL与艾伯维达成专利纠纷和解
和解
BTL宣布已解决其针对艾伯维、涉及BTL肌肉刺激技术的专利侵权索赔。根据和解协议,艾伯维将向BTL支付未披露金额,双方未决诉讼将撤销。
来源摘录
Under the terms of the settlement agreement, ABBVIE will pay BTL an undisclosed payment.
BTL Industries—a leading manufacturer of innovative aesthetic products—announced today that the company has resolved its patent infringement claims against ABBVIE related to BTL's muscle stimulation technology.
2021
AbbVie 对 Alvotech 提起第二起诉讼
提起诉讼
AbbVie 在伊利诺伊州北区对 Alvotech hf. 提起第二起诉讼,指控其涉及 Alvotech 拟议的 HUMIRA 生物类似药的专利侵权。
来源摘录
On May 28, AbbVie brought a second action in the Northern District of Illinois for patent infringement against Alvotech hf. under the BPCIA in connection with Alvotech’s proposed biosimilar version of HUMIRA® (adalimumab).
2021
Alvotech 就 Humira 专利起诉 AbbVie
提起诉讼
Alvotech USA 与 Alvotech hf 在弗吉尼亚东区法院对 AbbVie 提起确认判决诉讼,指称 AbbVie Humira 专利组合中的专利无效或不可执行,并请求法院作出不侵权及专利无效的确认判决。
来源摘录
For each patent, the complaint asserts a claim for a declaratory judgment of non-infringement and invalidity.
On May 11, 2021, Alvotech USA and Alvotech hf (jointly, Alvotech) filed a complaint seeking declaratory judgement against AbbVie Inc. and AbbVie Biotechnology Ltd (jointly, AbbVie) in the Eastern District of Virginia.
2020
2020
艾伯维就 HUMIRA 营销相关指控与加州达成和解
和解
艾伯维就涉嫌违反加州《保险欺诈预防法》的指控与加州达成和解。协议要求其改变 HUMIRA 的营销做法并支付 2,400 万美元;艾伯维仍否认存在不当行为。
品牌回应
否认 — AbbVie
The company also agreed to pay $24 million as part of the settlement despite continuing to deny any wrongdoing.
来源摘录
The settlement, reached Thursday, includes AbbVie’s agreement to alter its marketing practices for the drug HUMIRA, which is used primarily to treat inflammatory conditions like psoriasis, arthritis and Crohn’s Disease.
The pharmaceutical company AbbVie, Inc. has reached a settlement agreement with California over allegations that it violated the state’s Insurance Frauds Prevention Act.
The company also agreed to pay $24 million as part of the settlement despite continuing to deny any wrongdoing.
2018